LCID has enjoyed a pleasant 2022 so far, as the electric vehicle (EV) maker is up more than 8% year-to-date (YTD). Last year Lucid’s Air model went on to win the acclaimed MotorTrend Car of the Year award. However, we should keep in mind an upcoming catalyst that has the potential to affect LCID stock. On Jan. 19, the lockup period for existing shareholders of Lucid will expire. These types of lockup provisions are common for companies such as Lucid that opted to make their public debut by way of a special purpose acquisition company (SPAC) merger. And while LCID stock’s recent performance has been good, some early investors will likely take the opportunity to offload shares, particularly as slower growth has been predicted for the EV sector in 2022. This isn’t great news for Lucid, as inv

What happened? Ford stock surged 11.7% to $24.31 Tuesday, its highest close since Aug. 10, 2001, according to Dow Jones Market Data. The S&P 500 slipped 0.1%, while the Dow Jones Industrial Average fell 0.6%. Ford stock is now up 17% so far in 2022 after rising 136% in 2021. Tesla stock, for its part, is up 9% so far in 2022, after a 50% gain in 2021. As we all know, Ford announced that its F-150 Lightning electric pickup truck is moving to the final phase of pre-production, with vehicles coming off the assembly line to go through testing. The company plans to drive vehicles for thousands of miles to see whether they can stand up to the rigors of real-world driving while maintaining the durability that customers expect. What's more Ford beats out Tesla as top-perfor

What happened? The company reported a third-quarter net income of $74 million, or a loss of 5 cents a share on a diluted basis, compared with a loss of $130 million, or 23 cents a share, in the year-ago period. Adjusted earnings, which exclude stock-based compensation expenses and other items, were break-even a share.  Earlier this year, BlackBerry stock was included in the so-called meme basket targeted by retail traders who sent shares soaring. In January, the stock touched as high as $28.77 a share but it has since been cut to about a third that price. Shares have still outpaced the broader market, closing Tuesday up almost 40% since Jan. 1. Some facts. Long gone are the days when a BlackBerry (BB) phone would make an ideal Christmas gift, although investors will be looking fo

Electric vehicle investors are well aware that Nio's stock has had a tough 2021, in part because the company had no new models while rivals including Xpeng and Li Auto launched new or substantially revised vehicles. But with the ET5, the ET7's launch confirmed for March, and at least one more new Nio expected before the end of next year, 2022 is already shaping up to be a different story. That, and not the latest COVID variant, is what Nio investors should be focused on right now. You must know this! Shares of Nio set their all-time high back on Jan. 11, when they traded at $66.99 at some point during the day. On this Monday, the stock is down about 58% from that all-time high. What's more important, the company delivered 24,439 EVs in the third quarter of th

Who is GRTX? $Galera Therapeutics, Inc.(GRTX)$ Galera Therapeutics, Inc. (Nasdaq: GRTX) is a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutic candidates that have the potential to transform radiotherapy in cancer. Galera’s selective dismutase mimetic product candidate avasopasem manganese (GC4419, also referred to as avasopasem) is being evaluated for radiotherapy-induced toxicities. The Company’s second product candidate, rucosopasem manganese (GC4711, also referred to as rucosopasem), is in clinical-stage development to augment the anti-cancer efficacy of stereotactic body radiation therapy in patients with non-small cell lung cancer and locally adv

One of the best-performing stocks in the market in recent weeks has been Longeveron (NASDAQ:LGVN). Yesterday , LGVN stock is soaring once again, up nearly 150% at the end of the day. Among speculative biotech stocks, Longeveron continues to outperform the market by a wide margin. Trading at only $3 per share a week ago, shares of LGVN stock have skyrocketed to more than $40 per share yesterday. So what's behind the huge gain? An epic short squeeze appears to be underway. Longeveron announced on Nov. 18 that the U.S. Food and Drug Administration (FDA) granted a Rare Pediatric Disease designation to experimental drug Lomecel-B in treating a rare congenital heart defect. Since then, the company's shares have vaulted higher. The big increase was fueled by short-sellers closing their positions